ViroCell will manufacture viral vectors for the Zayed Centre for Research at the Great Ormond Street Hospital in London. (Credit: ViroCell)

November 1, 2023 03:00 AM EDTUpdated 09:12 AM

ViroCell to operate from a London facility to manufacture viral vectors for clinical trials

Anna Brown

News Reporter

Viral vector manufacturer ViroCell Biologics is leasing its first-ever facility — located at Great Ormond Street Hospital in London — so it can offer its services for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ViroCell to operate from a London facility to manufacture viral vectors for clinical trials

Anna Brown

News Reporter

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Exclusive: Florida cancer biotech raises $100M Series A

Vi­ro­Cell to op­er­ate from a Lon­don fa­cil­i­ty to man­u­fac­ture vi­ral vec­tors for clin­i­cal tri­als

Anna Brown

News Reporter

Sign up to read this article for free.

more like this

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

ViroCell to operate from a London facility to manufacture viral vectors for clinical trials

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Exclusive: Florida cancer biotech raises $100M Series A